AbbVie said the FDA has approved an antibody-drug conjugate it obtained as a part of its $10.1 billion buyout of ImmunoGen for an ultra-rare but aggressive form of blood cancer.
May 28, 2026 07:20 AM EDT
Pharma
AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
Ayisha Sharma
News Reporter
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
Best Biotech Stocks Right Now • Updated Daily • Benzinga
Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal
After prior FDA manufacturing snub, Gilead's hepatitis D med Hepcludex nabs US nod
AbbVie’s ultra-rare blood cancer ADC secured FDA clearance while AstraZeneca’s oral SERD for breast cancer remains in regulatory…
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere,…
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer,…
Trial results for Lilly's "triple-G" drug, FDA's leadership purge leaves chaos, and more biotech news from The Readout
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
